CN117396203A - 食欲素2受体激动剂用于术后恢复的用途 - Google Patents

食欲素2受体激动剂用于术后恢复的用途 Download PDF

Info

Publication number
CN117396203A
CN117396203A CN202280037124.XA CN202280037124A CN117396203A CN 117396203 A CN117396203 A CN 117396203A CN 202280037124 A CN202280037124 A CN 202280037124A CN 117396203 A CN117396203 A CN 117396203A
Authority
CN
China
Prior art keywords
compound
subject
salt
methyl
opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280037124.XA
Other languages
English (en)
Chinese (zh)
Inventor
木村东英
铃木基久
J·克罗尼卡恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN117396203A publication Critical patent/CN117396203A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280037124.XA 2021-04-02 2022-04-01 食欲素2受体激动剂用于术后恢复的用途 Pending CN117396203A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170211P 2021-04-02 2021-04-02
US63/170,211 2021-04-02
PCT/IB2022/053085 WO2022208478A1 (en) 2021-04-02 2022-04-01 Use of an orexin 2 receptor agonist for post operation recovery

Publications (1)

Publication Number Publication Date
CN117396203A true CN117396203A (zh) 2024-01-12

Family

ID=81326367

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280037124.XA Pending CN117396203A (zh) 2021-04-02 2022-04-01 食欲素2受体激动剂用于术后恢复的用途

Country Status (12)

Country Link
US (1) US20240165092A1 (https=)
EP (1) EP4313045A1 (https=)
JP (1) JP2024511676A (https=)
KR (1) KR20230165782A (https=)
CN (1) CN117396203A (https=)
AU (1) AU2022252108A1 (https=)
BR (1) BR112023020104A2 (https=)
CA (1) CA3215906A1 (https=)
CO (1) CO2023013001A2 (https=)
MX (1) MX2023011669A (https=)
TW (1) TW202304437A (https=)
WO (1) WO2022208478A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202502342A (zh) * 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
PL3411358T3 (pl) * 2016-02-04 2022-02-28 Takeda Pharmaceutical Company Limited Podstawiony związek piperydynowy i jego zastosowanie
US11034700B2 (en) 2017-03-08 2021-06-15 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
WO2018164191A1 (ja) 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US20200207734A1 (en) 2017-08-03 2020-07-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US12077522B2 (en) 2018-06-29 2024-09-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
JP7413261B2 (ja) 2018-06-29 2024-01-15 武田薬品工業株式会社 複素環化合物およびその用途
EP3896060B1 (en) 2018-12-12 2023-08-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
SG11202106791XA (en) 2019-01-31 2021-07-29 Takeda Pharmaceuticals Co Heterocyclic compound and use thereof
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CA3154321A1 (en) * 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy

Also Published As

Publication number Publication date
WO2022208478A1 (en) 2022-10-06
KR20230165782A (ko) 2023-12-05
CO2023013001A2 (es) 2023-10-30
US20240165092A1 (en) 2024-05-23
CA3215906A1 (en) 2022-10-06
JP2024511676A (ja) 2024-03-14
AU2022252108A1 (en) 2023-10-05
BR112023020104A2 (pt) 2023-11-14
MX2023011669A (es) 2023-10-18
TW202304437A (zh) 2023-02-01
EP4313045A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
JP6931019B2 (ja) 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
US20120101073A1 (en) Novel Method For Treating Breathing Disorders or Diseases
US20120270848A1 (en) Novel Compositions and Therapeutic Methods Using Same
JPWO2007086493A1 (ja) 経鼻投与用薬剤
WO2012166909A1 (en) Compositions and methods for treating breathing control disorders or diseases
CN101674819A (zh) S1p受体调节剂的用途
CN101203217A (zh) 调节膀胱功能的方法
TW200831097A (en) Treatment of anxiety with eszopiclone
JP2020502215A (ja) Ｔａｓｋ−１およびｔａｓｋ−３チャネル阻害剤を含む医薬剤形、ならびに呼吸障害療法におけるその使用
US10881633B2 (en) Compositions and methods for stimulating ventilatory and/or respiratory drive
AU779696B2 (en) Methods for treating apnea and apnea disorders using optically pure R(+)ondansetron
JP2022502374A (ja) 睡眠時無呼吸の治療のためのα２‐アドレナリン受容体サブタイプＣ （ＡＬＰＨＡ‐２Ｃ）拮抗薬
CN117396203A (zh) 食欲素2受体激动剂用于术后恢复的用途
JP2005531612A (ja) ネフォパムの製剤および痛みの治療におけるその使用
EP3400940B1 (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
US20100105685A1 (en) S-Nitrosothiol Compounds and Related Derivatives
WO2024139978A1 (zh) Vofopitant用于治疗肺纤维化的用途
US20100035998A1 (en) Combination s-nitrosothiol pharmaceutical products for restoring normal breathing rhythms
JP2005513105A (ja) 臨床的うつ病を治療するためのデオキシペガニンの使用
JP2008255064A (ja) 睡眠障害予防治療剤
KR20240053061A (ko) 수면 무호흡증을 치료하기 위한 방법 및 조성물
WO2022004788A1 (ja) 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤
US11858908B2 (en) Compositions and methods for inhibiting IDO1
WO2021021005A1 (ru) Применение производных n,n'-замещенных 3,7-диазабицикло[3.3.1]нонанов для терапии депрессии
CN111670041A (zh) 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination